Quick Answer
Silexion Therapeutics Corp reported Stockholders Equity of $2.60 million for the year ending 2025.
- Silexion Therapeutics Corp showed an increase of +165.3% in Stockholders Equity from 2024 to 2025.
- This data is from Silexion Therapeutics Corp's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: -$18.26 million | Q3 2024: -$4.58 million | Q1 2025: $2.59 million | Q2 2025: $120.0 thousand | Q3 2025: $6.98 million.
- Over the full 3 years of available data (2023 to 2025), Silexion Therapeutics Corp's Stockholders Equity has grown by 116.8%.
- Historical annual values: Fiscal year 2025: $2.60 million | Fiscal year 2024: -$3.99 million | Fiscal year 2023: -$15.48 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: